Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 2,346 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 3 Interventional

Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency

NCT00709865
View directory record Official record
Conditions
Renal Insufficiency, Congestive Heart Failure
Interventions
tonapofylline, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
68
States / cities
Huntsville, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 10, 2026, 1:59 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT03452137
View directory record Official record
Conditions
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Atezolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Duarte, California • La Jolla, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

American Trial Using Tranexamic Acid in Thrombocytopenia

NCT02578901
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Participants

NCT03375463
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis

NCT02866721
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Mesenchymal Stem Cells
Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

NCT04449484
View directory record Official record
Conditions
Parkinson's Disease
Interventions
MEDI1341, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 10, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

NCT05879718
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
Interventions
Placebo, PF-06823859
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 1:59 PM EDT
Active, not recruiting Phase 3 Interventional

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

NCT06634420
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
NTLA-2002, Normal Saline IV Administration
Biological
Lead sponsor
Intellia Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 4 Interventional

Tranexamic Acid for Total Knee Arthroscopy

NCT04443920
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Tranexamic acid (TXA), Placebo Normal Saline (NS)
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

NCT00878878
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Elliott, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Magnesium Supplementation in People With XMEN Syndrome

NCT02496676
View directory record Official record
Conditions
XMEN
Interventions
Magnesium L-threonate, Placebo, Intravenous (IV) magnesium sulfate (MgSO4)
Dietary Supplement · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT04619797
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 10, 2026, 1:59 PM EDT
Suspended Phase 2 Interventional

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115
View directory record Official record
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

NCT01597947
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ACHN-975, placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

NCT01960348
View directory record Official record
Conditions
TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Interventions
patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
La Mesa, California • Orange, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

NCT00482989
View directory record Official record
Conditions
Lupus
Interventions
MEDI 545, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
18
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

NCT03930615
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Letermovir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

NCT04497987
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
Bamlanivimab, Placebo, Etesevimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin for Systemic Sclerosis

NCT03222492
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions
Brentuximab Vedotin, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 10, 2026, 1:59 PM EDT
Withdrawn Phase 2 Interventional

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

NCT03005184
View directory record Official record
Conditions
Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

NCT00623363
View directory record Official record
Conditions
Parkinson's Disease
Interventions
piclozotan, 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
40 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

NCT03772587
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
M281, Placebo
Drug · Other
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 10, 2026, 1:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

NCT00223704
View directory record Official record
Conditions
Cardiopulmonary Bypass, Inflammation, Fibrinolysis, Surgery
Interventions
HOE 140, Aminocaproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 10, 2026, 1:59 PM EDT